Communities Fighting COVID-19!

Study Overview
=================
Brief Summary
-----------------
To create and evaluate effective COVID-19 testing uptake strategies that focus on underserved individuals who are exposed but have not accessed testing, and underserved individuals who are not routinely tested because they are unaware of their exposure or risk status in order to increase testing among these populations and reduce Covid-19 related disparities.

Detailed Description
-----------------
Communities Fighting COVID is a partnership between San Diego State's School of Public Health and numerous communities in San Diego focused on providing community-based testing to specific language-speaking communities and vulnerable populations. This partnership is funded by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics-Undeserved Populations (Radx-UP), with the aim of ensuring all Americans have access to timely COVID-19 testing and diagnosis. Many communities, particularly immigrant and people of color communities, have a harder time accessing existing COVID-19 resources due to transportation, language barriers, or other barriers.

Official Title
-----------------
Communities Fighting COVID!

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Other: COVID-19 Testing Home-based (Aim 1)
* Other: COVID-19 Testing Mobile (Aim 1)
* Other: COVID-19 Testing Mobile Approach 1 (Aim 2)
* Other: COVID-19 Testing Mobile Approach 2 (Aim 2)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: African American, Arabic speaking, Filipino, and Latino/a populations Exclusion Criteria: Younger than 6, not in focus populations

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Cluster Randomized Trial
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: At home testing (Aim 1)<br>High-risk friends and family of contacts exposed to COVID-19 will be provided with COVID-19 testing provided at home by a healthcare worker. | Other: COVID-19 Testing Home-based (Aim 1)<br>* Implementation of Antigen and PCR testing at participant homes<br>|
| Active Comparator: Mobile testing (Aim 1)<br>High-risk friends and family of contacts exposed to COVID-19 will be referred to study operated mobile testing sites in the community for COVID-19 testing. | Other: COVID-19 Testing Mobile (Aim 1)<br>* Implementation of Antigen and PCR testing at mobile test sites<br>|
| Other: Mobile testing approach 1 (Aim 2)<br>Mobile testing utilizing active outreach | Other: COVID-19 Testing Mobile Approach 1 (Aim 2)<br>* Implementation of Antigen and PCR testing at mobile test sites - active outreach<br>|
| Other: Mobile testing approach 2 (Aim 2)<br>Mobile testing utilizing baseline outreach approaches | Other: COVID-19 Testing Mobile Approach 2 (Aim 2)<br>* Implementation of Antigen and PCR testing at mobile test sites - baseline outreach<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Test uptake | Testing volume by study arm as cumulative count per hours testing site operated | Through study completion, expected to be 20 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Test access | Proportion of individuals by study arm who note that this strategy has facilitated ability to test. | Through study completion, expected to be 20 months | 
| Test Impact (COVID-19 diagnoses) | Proportion of COVID-19 diagnoses of those tested by study arm | Through study completion, expected to be 20 months | 
| Test Impact (number needed to screen) | Number needed to screen (number tested in order to detect one new infection). | Through study completion, expected to be 20 months |